JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

3.14 -2.48

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.06

Max

3.17

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-15M 24M
Vorheriger Eröffnungskurs	5.62
Vorheriger Schlusskurs	3.14

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Apr. 2026, 23:08 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 23:07 UTC

Ergebnisse

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:20 UTC

Ergebnisse

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. Apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. Apr. 2026, 23:22 UTC

Ergebnisse

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. Apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. Apr. 2026, 22:52 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:33 UTC

Ergebnisse

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. Apr. 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. Apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. Apr. 2026, 22:05 UTC

Ergebnisse

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 21:57 UTC

Ergebnisse

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. Apr. 2026, 21:55 UTC

Ergebnisse

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. Apr. 2026, 21:53 UTC

Ergebnisse

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.